Author

Marieke Schurer

Observed names: M. Schurer, Schurer, Marieke

Observed institutions: University Medical Center Utrecht, BresMed, ProRail

OpenAlex ID: A5071614419

Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands

2021 · Marieke Schurer, Suzette M. Matthijsse, et al. · Value in Health · 40

Patient and caregiver experiences of living with acute hepatic porphyria in the UK: a mixed-methods study

2021 · Liz Gill, Sue Burrell, et al. · Orphanet Journal of Rare Diseases · 15

The journey to diagnosis of wild-type transthyretin-mediated (ATTRwt) amyloidosis: a path with multisystem involvement

2024 · Chafic Karam, Colleen Moffit, et al. · Orphanet Journal of Rare Diseases · 14

Recent advances in addressing the market failure of new antimicrobials: Learnings from NICE's subscription-style payment model

2023 · Marieke Schurer, Renu Patel, et al. · Frontiers in Medical Technology · 10

Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

2021 · Ann-Marie Chapman, Marieke Schurer, et al. · BMC Neurology · 8

Pns6 the Use of Variable Willingness-to-pay Thresholds in Hta Decision-making to Reflect Societal Values for Healthcare Provision

2019 · J. Horscroft, E. Jones, et al. · Value in Health · 1

European HTA, Pricing And Reimbursement Roadmaps: Revisited 2016

2016 · N. Mason, M. Schurer · Value in Health · 1

Health state utility values in children with peanut allergy and their caregivers: a UK vignette study

2026 · Marieke Schurer, Emily Jones, et al. · Health and Quality of Life Outcomes

HTA30 Behavioural Structured Expert Elicitation: A Case Study to Inform Hospitalisation Due to Respiratory Syncytial Virus in the UK

2023 · M. Schurer, J. Horscroft, et al. · Value in Health

The Journey to Diagnosis of Wild-type Transthyretin-mediated Amyloidosis: A Path with Multisystem Involvement

2023 · Colleen Moffitt, Chafic Karam, et al. · Heart & Lung

The Journey To Diagnosis Of Wild-type Attr Amyloidosis: A Path With Multisystem Involvement

2023 · Chafic Karam, Catherine Summers, et al. · Journal of Cardiac Failure

PRO15 Healthcare Resource Utilization Associated with NON-Dystrophic Myotonia: Results from a Delphi Panel

2021 · A. Omar, A.M. Chapman, et al. · Value in Health

Pmu82 Varying Willingness-to-pay Based on Disease Burden: Impact on Health Technology Assessment Outcomes of Specialist Drugs in the Netherlands

2019 · M. Schurer, C.Y. Vossen, et al. · Value in Health

Pmu114 Specialised Health Technology Assessment Processes for Very Rare Diseases: Past, Present and Future

2019 · R.L. Akehurst, J.A. Moorhouse, et al. · Value in Health

Are Orphan Drugs Treated the Same Across Europe: an Hta Case Study

2016 · M. Schurer, N. Mason · Value in Health

Works count: 27

Citation count: 89

H-index: 5

I10-index: 4